Insider · CIK 0002066645
Robert Charles Breedlove
Files at PHAT (Phathom Pharmaceuticals, Inc.). First filing Jul 18, 2025, latest Nov 5, 2025.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
PHAT: Phathom Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | PHATsell Phathom Pharmaceuticals, Inc. | $7,079 524 shares | -1% | +500% from low-28% from high | |
| 15Weak | PHATsell Phathom Pharmaceuticals, Inc. | $5,573 461 shares | -1% | +439% from low-37% from high | |
| 15Weak | PHATsell Phathom Pharmaceuticals, Inc. | $14k 1,692 shares | -3% | +264% from low-57% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 3, 2026 | PHAT Phathom Pharmaceuticals, Inc. | FTax withholding Common Stock | -460 | $9.05 | $4,163 | 59,465 | 34 d ago |
| Dec 18, 2025 | PHAT Phathom Pharmaceuticals, Inc. | FTax withholding Common Stock | -230 | $16.28 | $3,744 | 47,844 | Dec 19, 2025 |
| Nov 3, 2025 | PHAT Phathom Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -524 | $13.51 | $7,079 | 47,407 | Nov 5, 2025 |
| Sep 5, 2025 | PHAT Phathom Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -461 | $12.09 | $5,573 | 47,931 | Sep 9, 2025 |
| Jul 16, 2025 | PHAT Phathom Pharmaceuticals, Inc. | SOpen-market sale Common Stock | -1,692 | $8.36 | $14k | 48,392 | Jul 18, 2025 |
| May 19, 2025 | PHAT Phathom Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +33,000 | $0.00 | $0 | 33,000 | May 21, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.